



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



Rat anti CD39, Ectonucleoside triphosphate diphosphohydrolase 1

Catalogue number: **MUB2012P**

Clone	R22
Isotype	IgG1
Product Type	Primary Antibodies
Units	0.1mg
Host	Rat
Species reactivity	Human
Application	Flow cytometry

Background

CD39 is a transmembrane cell surface protein, which is a member of the ecto-nucleoside triphosphate diphosphohydrolase (ENTPDase) family. The CD39 molecule is primarily involved in the metabolism of purine nucleotides, converting extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate (AMP). In conjunction with CD73 (5' nucleotidase), CD39 plays a key role in regulating immunity and inflammation through the production of adenosine and purinergic signalling pathways. In addition, CD39 is reported to mediate B cell homotypic adhesion and inhibit ADP-induced platelet aggregation. CD39 was originally identified on Epstein Barr virus transformed B cell lines and described as a B-cell activation marker. However, subsequent studies have shown that CD39 is also expressed on activated T-cells, T-regulatory cells, natural killer cells, tissue macrophages and endothelial cells. Increased expression of CD39 has also been reported in cases of chronic lymphocytic leukaemia and several solid tumours including colorectal and pancreatic cancer suggesting a potential role for CD39 in tumour development and progression.

Source

R22 is a rat monoclonal IgG1 antibody derived by fusion of SP2/0 mouse myeloma cells with splenocytes from a WAG/Rij rat immunized with JY cells, a human B lymphoblastoid cell line.

Product

Each vial contains 100µl 1mg/ml purified monoclonal antibody in phosphate buffered saline (PBS) containing 0.09% sodium azide.

Distributors

For Purchasing Information, please contact your local distributor

[Find Distributor](#)

Applications

The R22 antibody is suitable for the detection of human CD39 antigen by flow cytometry. Human spleen is suitable as a positive control. Optimal antibody dilutions for the different applications should be determined by titration.

Specificity

The antibody R22 is directed against human CD39. The antibody has not been tested for cross reactivity with other species.

Storage

Store at 4°C, or in small aliquots at -20°C.

References

1. Kansas GS, Wood GS, Tedder TF. (1991). Expression, distribution and biochemistry of CD39. *J Immunol.* 146:2235–2244.

Caution

This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.